

Acknowledgement

The IAEA acknowledges the contributions to IPET 2011 from the following companies:

Best Theratronics Ltd
Biodex Medical Systems
Canberra Packard CE GmbH
COMECER
Elimpex
GE Healthcare Technologies
IASON GmbH
IBA Molecular
ITG Isotope Technologies
MEDISO
PiCHEM GmbH
Raytest GmbH
Saxons International
Siemens AG
Tema Sinergie

The contributions have been used to support scientists from developing countries in attending this conference.

The fact that the IAEA has made facilities available for companies to exhibit at the conference does not imply that it endorses the equipment and products exhibited.

Programme Committee:

R. Fulton, Australia	F. Mut, Uruguay
V. Kumar, Australia	G. El Fakhri, USA
H. Patterson, Australia	D. Schlyer, USA
A. Scott, ANZSNM	E. Estrada Lobato, WFNMB
C. Chow Robilotta, Brazil	M. Dondi, IAEA
A. Chiti, EANM	M. Haji-Saeid, IAEA
C. Decristoforo, EANM	D. Paez, IAEA
B. Krause, EANM	S. Palm, IAEA
A. Malhotra, India	T. Pascual, IAEA
A. Kesner, Israel	M.R. Ambi Pilai, IAEA
M. Marengo, Italy	R. Kashyap, IAEA
P. Elsinga, Netherlands	J. Zaknun, IAEA
Y. Fujibayashi, SMI	U.S. Bhonsle, IAEA
G. Segall, SNM	A. Duatti, IAEA

IAEA Secretariat:

Scientific Secretaries:	M. Dondi M. Haji-Saeid D. Paez S. Palm
Administrative Support:	M. Ivanov N. El-Haj A.J. Domingo
Conference Coordination:	D. Schwingenschloegl K. Morrison
Exhibition Coordination:	B. Keceli Meszaros M. Neuhold
TC Coordination:	S. Steyskal A. Cardoso

Location of the Conference:

International Atomic Energy Agency
Vienna International Centre (VIC)
M Building
1400 Vienna, Austria
Tel.: (+43 1) 2600 21324
Fax: (+43 1) 2600 7

Working Language: English**Resolutions:** No resolutions may be submitted for consideration on any subject; no votes will be taken.

TIMETABLE

Monday, 7 November 2011

15:00–18:00 Registration and distribution of conference material Gate 1

Tuesday, 8 November 2011

08:00 Registration Gate 1
 08:00 Distribution of conference material M Building
 09:30–10:00 Opening Session (Boardroom A)
 10:00–12:30 Plenary Session I PET in Cancer Management (Boardroom A)
 12:30–14:00 Lunch Break
 14:00–15:30 Parallel Session Ia Clinical PET I (Boardroom A)
 14:00–15:30 Parallel Session Ib Radiopharmacy and Instrumentation I (Conference Room M3)
 15:30–16:00 Coffee/Tea Break
 16:00–17:00 Poster Review – Session I Clinical PET Part I
 17:00–18:00 Plenary Session II Radiation Safety (Boardroom A)
 18:00–18:30 Side Event Human Health Campus (Boardroom A)
 18:30–20:00 Welcome Reception

Wednesday, 9 November 2011

08:30–11:00 Plenary Session III Therapy Response, Cost Effectiveness and PET in Paediatrics (Boardroom A)
 11:00–11:30 Coffee/Tea Break
 11:30–12:30 Plenary Discussion I Panel Discussion: ARCCNM - Sustainability of Clinical PET in Asia (Boardroom A)
 12:30–14:00 Lunch Break
 14:00–15:30 Parallel Session IIa Clinical PET II (Boardroom A)
 14:00–15:30 Parallel Session IIb Radiopharmacy II (Conference Room M3)
 14:00–15:30 Parallel Session IIc Physics and Instrumentation II (Conference Room M6)
 15:30–16:00 Coffee/Tea Break
 16:00–17:00 Poster Review – Session II Clinical PET Part II and Clinical non-PET
 17:00–18:00 Plenary Session IV Quality Assurance – Quality Control (Boardroom A)

Thursday, 10 November 2011

08:30–10:30 Plenary Session V PET in Neurology (Boardroom A)
 10:30–11:00 Coffee/Tea Break
 11:00–12:30 Plenary Session VI PET in Cardiology (Boardroom A)
 12:30–14:00 Lunch Break
 14:00–15:30 Parallel Session IIIa Clinical PET III (Boardroom A)
 14:00–15:30 Parallel Session IIIb Radiopharmacy III (Conference Room M3)
 14:00–15:30 Parallel Session IIIc Physics and Instrumentation III (Conference Room M6)
 15:30–16:00 Coffee/Tea Break
 16:00–17:00 Poster Review – Session III Radiopharmacy PET, Radiopharmacy non-PET, Instrumentation and Quality Control, Dosimetry and Radiation Safety, Education and Training, Planning/Establishing/Experiences PET Centres
 17:00–18:00 Plenary Discussion II Panel Discussion: WFNMB - Issues and Challenges for Nuclear Medicine Education and Training (Boardroom A)

Friday, 11 November 2011

08:30–10:30 Plenary Session VII Miscellaneous: PET/CT and SPECT/CT (Boardroom A)
 10:30–11:00 Coffee/Tea Break
 11:00–12:30 Plenary Session VIII New Directions of Radiopharmacy and Instrumentation (Boardroom A)
 12:30–13:30 Lunch Break
 13:30–14:30 Plenary Session IX Closing Session (Boardroom A)

Posters will be displayed as follows in the ground floor corridors of buildings A, B, and C:

- Tue, 8 November 2011: Clinical PET I
(*Oncology, Cardiology, Neurology and Paediatrics*)
- Wed, 9 November 2011: Clinical PET II (*Other applications*)
& Clinical non-PET
- Thu, 10 November 2011: Radiopharmacy PET,
Radiopharmacy non-PET,
Instrumentation and Quality Control,
Dosimetry and Radiation Safety,
Education and Training,
Planning/Establishing/ Experiences
PET Centres

Commercial exhibits will be shown in the M building (ground floor and second floor) from Tuesday to Friday, 8–11 November 2011.

MONDAY, 7 NOVEMBER 2011

15:00–18:00 **Registration and distribution of
conference material**

TUESDAY, 8 NOVEMBER 2011

08:00 **Registration and distribution of
conference material**

09:30–10:00 **OPENING SESSION**

Room: **Boardroom A**

D. Mohamad, IAEA

Deputy Director General
Head of Department of Nuclear Sciences
and Applications

K. Aning, IAEA

Deputy Director General
Head of Department of
Technical Cooperation

R.K. Chhem, IAEA

Director
Division of Human Health
Department of Nuclear Sciences
and Applications

M. Venkatesh, IAEA

Director
Division of Physical and Chemical Sciences
Department of Nuclear Sciences
and Applications

TUESDAY, 8 NOVEMBER 2011

10:00–12:30 **PLENARY SESSION I**
PET in Cancer Management

Room: **Boardroom A**

Chairperson: **H. Macapinlac, United States of America**
IAEA Coordinator: **D. Paez**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
10:00–10:30	INV001	C. Buchpiguel	WFNMB	Role of PET in Developing Countries and the Role of the IAEA in Supporting the Development of PET
10:30–11:00	INV002	G. Segall	SNM	The Importance of PET in Human Health
11:00–11:30	INV003	D. Delbeke	SNM	PET in Cancer Management
11:30–12:00	INV004	A. Chiti	EANM	PET in Radiation Treatment Planning
12:00–12:30	INV005	C. Anderson	SNM	New PET Radiopharmaceuticals: Applications for Imaging Tumour Receptors and the Tumour Microenvironment
<hr/>				
12:30–14:00	<i>Lunch Break</i>			

14:00–15:30 **PARALLEL SESSION Ia**
Clinical PET I

Room: **Boardroom A**

Chairperson: **C. Buchpiguel, WFNMB**
IAEA Coordinator: **D. Paez**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
14:00–14:45	INV006	J.A. Obando	United States of America	Cross Sectional Anatomy: Head and Neck
14:45–15:30	INV007	H. Macapinlac	United States of America	Read with the Expert: PET/CT Head and Neck

TUESDAY, 8 NOVEMBER 2011

14:00–15:30 **PARALLEL SESSION Ib**
Radiopharmacy and Instrumentation I
Panel Discussion: Planning a PET Facility

Room: **Conference Room M3**

Chairperson: **G. El Fakhri, United States of America**

IAEA Coordinator: **A. Duatti**

S. Palm

Rapporteur: **V. Kumar, Australia**

Panel Members *Designating Member State/Organization*

G. El Fakhri United States of America

E. Estrada Lobato WFNMB

J. Froelich United States of America

V. Kumar Australia

M. Marengo Italy

M. Mitterhauser Austria

H. Patterson Australia

15:30–16:00 *Coffee/Tea Break*

16:00–17:00 **POSTER REVIEW – SESSION I**
Clinical PET Part I (Oncology, Cardiology
Neurology, and Paediatrics)

Location: **Corridor A, B, C: Ground Floor**

IAEA Coordinator: **T. Pascual**

Poster Reviewers *Designating Member State/Organization*

E. Alexanderson Mexico

H.S. Bom ARCCNM

A. Chiti EANM

E. Estrada Lobato WFNMB

R. Howman-Giles Australia

B. Krause EANM

S. Minoshima United States of America

G. Segall SNM

J. Soares Junior Brazil

TUESDAY, 8 NOVEMBER 2011

17:00–18:00 **PLENARY SESSION II**
Radiation Safety

Room: **Boardroom A**

Chairperson: **M. Marengo, Italy**
IAEA Coordinator: **S. Palm**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
17:00–17:30	INV008	M.M. Rehani	IAEA	Reduction of Patient Radiation Exposure from PET/CT
17:30–18:00	INV009	D. Delbeke	SNM	Controversy 1: Risk Versus Benefits

18:00–18:30 **SIDE EVENT**
Human Health Campus

Room: **Boardroom A**

IAEA Coordinator: **M. Dondi**

Presenters: **R. Kashyap, IAEA**
 D. Paez, IAEA

18:30–20:00 *Welcome Reception*

WEDNESDAY, 9 NOVEMBER 2011

08:30–11:00 **PLENARY SESSION III**
Therapy Response, Cost Effectiveness
and PET in Paediatrics

Room: **Boardroom A**

Chairperson: **J.A. Obando, United States of America**
IAEA Coordinator: **R. Kashyap**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
08:30–09:00	INV010	B. Krause	EANM	PET in Evaluation of Therapy
09:00–09:30	INV011	A. Chiti	EANM	Standardization and Quantitation
09:30–10:00	INV012	A. Scott	ANZSNM	Controversy 2: Quantitation - Is It Necessary for All Examinations?
10:00–10:30	INV013	H. Macapinlac	United States of America	Cost Effectiveness in PET/CT
10:30–11:00	INV014	R. Howman-Giles	Australia	Applications of PET/CT in Children and Adolescents

11:00–11:30 *Coffee/Tea Break*

11:30–12:30 **PLENARY DISCUSSION I**
Panel Discussion: ARCCNM –
Sustainability of Clinical PET in Asia

Room: **Boardroom A**

Chairperson: **H.S. Bom, ARCCNM**
IAEA Coordinator: **M. Dondi**
Rapporteur: **T. Pascual, IAEA**

Panel Members: V. Kumar, Australia
H. Macapinlac, United States of America
A. Malhotra, India
S. Solav, India
T. San Luis, ASNM
J. Soares Junior, Brazil

12:30–14:00 *Lunch Break*

WEDNESDAY, 9 NOVEMBER 2011

14:00–15:30 **PARALLEL SESSION IIa**
Clinical PET II

Room: **Boardroom A**

Chairperson: **R. Howman-Giles, Australia**
IAEA Coordinator: **D. Paez**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
14:00–14:45	INV015	J.A. Obando	United States of America	Cross Sectional Anatomy: Thorax
14:45–15:30	INV016	G. Segall	SNM	Read with the Expert: PET/CT Thorax

14:00–15:30 **PARALLEL SESSION IIb**
Radiopharmacy II
Panel Discussion:
How to Implement GMPs

Room: **Conference Room M3**

Chairperson: **V. Kumar, Australia**
IAEA Coordinator: **A. Duatti**
Rapporteur: **P. Elsinga, Netherlands**

Panel Members: C. Decristoforo, EANM
P. Elsinga, Netherlands
M. Mitterhauser, Austria
D. Schlyer, United States of America

14:00–15:30 **PARALLEL SESSION IIc**
Physics and Instrumentation II
Panel Discussion: Dose Reduction and
Radiation Protection for Personnel

Room: **Conference Room M6**

Chairperson: **F. Fahey, SNM**
IAEA Coordinator: **S. Palm**
Rapporteur: **K. Pathmaraj, ANZSNM**

Panel Members: K. Bacher, PEDDOSE.NET
C. Chow Robilotta, Brazil
F. Fahey, SNM
M. Nuñez, Uruguay
K. Pathmaraj, ANZSNM
M.M. Rehani, IAEA

15:30–16:00 *Coffee/Tea Break*

WEDNESDAY, 9 NOVEMBER 2011

16:00–17:00 **POSTER REVIEW – SESSION II**
Clinical PET Part II and Clinical non-PET

Location: **Corridor A, B, C: Ground Floor**

IAEA Coordinator: **T. Pascual**

Poster Reviewers *Designating Member State/Organization*

E. Alexanderson Mexico
H.S. Bom ARCCNM
C. Buchpiguel WFNMB
R. Howman-Giles Australia
S. Minoshima United States of America
T. San Luis ASNM
J. Soares Junior Brazil
C. Van de Wiele Belgium

17:00–18:00 **PLENARY SESSION IV**
Quality Assurance – Quality Control

Room: **Boardroom A**

Chairperson: **F. Fahey, SNM**

IAEA Coordinator: **A. Duatti**
U. Bhonsle

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
17:00–17:30	INV017	R. Fulton	Australia	QA and QC: Instrumentation
17:30–18:00	INV018	C. Decristoforo	EANM	QA and QC: Radiopharmaceuticals

THURSDAY, 10 NOVEMBER 2011

08:30–10:30 **PLENARY SESSION V**
PET in Neurology

Room: **Boardroom A**

Chairperson: **G. Segall, SNM**
IAEA Coordinator: **J. Zaknun**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
08:30–09:00	INV019	S. Minoshima	United States of America	Dementia
09:00–09:30	INV020	B. Buchpiguel	WFNMB	PET - Psychiatric Applications/Movement Disorders
09:30–10:00	INV021	A. Scott	ANZSNM	Brain Tumours
10:00–10:30	INV022	S. Minoshima	United States of America	Epilepsy

10:30–11:00 *Coffee/Tea Break*

11:00–12:30 **PLENARY SESSION VI**
PET in Cardiology

Room: **Boardroom A**

Chairperson: **D. Delbeke, SNM**
IAEA Coordinator: **R. Kashyap**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
11:00–11:30	INV023	E. Alexanderson	Mexico	CAD Evaluation: PET vs. SPECT
11:30–12:00	INV024	F.M. Bengel	Germany	PET Myocardial Viability Assessment
12:00–12:30	INV025	G. El Fakhri	United States of America	Innovations in PET and SPECT Cardiac Imaging

12:30–14:00 *Lunch Break*

THURSDAY, 10 NOVEMBER 2011

14:00–15:30 **PARALLEL SESSION IIIa**
Clinical PET III

Room: **Boardroom A**

Chairperson: **A. Scott, ANZSNM**
IAEA Coordinator: **D. Paez**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
14:00–14:45	INV026	J.A. Obando	United States of America	Cross Sectional Anatomy: Abdomen, Pelvis
14:45–15:30	INV027	D. Delbeke	SNM	Read with the Expert: PET/CT: Abdomen and Pelvis

14:00–15:30 **PARALLEL SESSION IIIb**
Radiopharmacy III
Panel Discussion:
Practical Aspects of F18, Cu64 and Ga68

Room: **Conference Room M3**

Chairperson: **C. Anderson, SNM**
IAEA Coordinator: **M. Haji-Saeid**
Rapporteur: **D. Schlyer, United States of America**

Panel Members: C. Anderson, SNM
C. Decristoforo, EANM
V. Kumar, Australia
D. Schlyer, United States of America

14:00–15:30 **PARALLEL SESSION IIIc**
Physics and Instrumentation III
Panel Discussion: Practical Aspects of CT

Room: **Conference Room M6**

Chairperson: **K. Bacher, PEDDOSE.NET**
IAEA Coordinator: **S. Palm**
Rapporteur: **C. Chow Robilotta, Brazil**

Panel Members: K. Bacher, PEDDOSE.NET
C. Chow Robilotta, Brazil
R. Howman-Giles, Australia
K. Pathmaraj, ANZSNM
C. Vandevoorde, PEDDOSE.NET

15:30–16:00 *Coffee/Tea Break*

THURSDAY, 10 NOVEMBER 2011

16:00–17:00 **POSTER REVIEW – SESSION III**
Radiopharmacy PET,
Radiopharmacy non-PET,
Instrumentation and Quality Control,
Dosimetry and Radiation Safety, Education
and Training, Planning/Establishing/
Experiences PET Centres

Location: **Corridor A, B, C: Ground Floor**

IAEA Coordinator: **T. Pascual**

Poster Reviewers Designating Member State/Organization

H.S. Bom	ARCCNM
P. Elsinga	Netherlands
E. Estrada Lobato	WFNMB
R. Fulton	Australia
M. Marengo	Italy
M. Núñez	Uruguay
H. Patterson	Australia
T. San Luis	ASNM
D. Schlyer	United States of America

17:00–18:00 **PLENARY DISCUSSION II**
Panel Discussion: WFNMB –
Issues and Challenges for Nuclear
Medicine Education and Training

Room: **Boardroom A**

Chairperson: **E. Estrada Lobato, WFNMB**

IAEA Coordinator: **M. Dondi**

Rapporteur: **T. San Luis, ASNM**

Panel Members: E. Estrada Lobato, WFNMB
F. Fahey, SNM
B. Krause, EANM
A. Malhotra, India
H. Patterson, Australia
T. San Luis, ASNM

FRIDAY, 11 NOVEMBER 2011

08:30–10:30 **PLENARY SESSION VII**
Miscellaneous: PET/CT and SPECT/CT

Room: **Boardroom A**

Chairperson: **B. Krause, EANM**
IAEA Coordinator: **J. Zaknun**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
08:30–09:00	INV028	C. Van de Wiele	Belgium	New Direction of PET: Infection, Inflammation and Bone Imaging
09:00–09:30	INV029	H. Macapinlac	United States of America	Clinical Applications of Non-FDG PET Tracers
09:30–10:00	INV030	S. Berlangieri	Australia	Structured PET/CT Reporting and Clinical Auditing
10:00–10:30	INV031	J. Froelich	United States of America	An Overview of Current Applications of SPECT/CT

10:30–11:00 *Coffee/Tea Break*

11:00–12:30 **PLENARY SESSION VIII**
New Directions of Radiopharmacy and Instrumentation

Room: **Boardroom A**

Chairperson: **C. Chow Robilotta, Brazil**
IAEA Coordinator: **U. Bhonsle**

<i>Time</i>	<i>No. of Paper IAEA–CN–185</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
11:00–11:30	INV032	P. Elsinga	Netherlands	Radiopharmaceutical Production
11:30–12:00	INV033	G. El Fakhri	United States of America	State of the Art and New Directions in Instrumentation: PET/MR, PET/CT, SPECT
12:00–12:30	INV034	Y. Fujibayashi	SMI	Translational Research: From Bench to Bedside

12:30–13:30 *Lunch Break*

FRIDAY, 11 NOVEMBER 2011

13:30–14:30 **PLENARY SESSION IX**
Closing Session

Room: **Boardroom A**

IAEA Coordinator: **M. Dondi**

13:30–14:00 Highlights & Trends

	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title</i>
13:30–13:40	B. Krause	EANM	Highlights in Clinical Nuclear Medicine
13:40–13:50	M. Marengo	Italy	Highlights in Dosimetry and Radiation Safety, Instrumentation and Quality Control
13:50–14:00	C. Anderson	SNM	Highlights in Radiopharmacy

14:00–14:20 Poster Awards

14:20–14:30 Closing Remarks
M. Dondi, IAEA

POSTERS

TUESDAY, 8 NOVEMBER 2011

Clinical PET I

(Oncology, Cardiology, Neurology and Paediatrics)

Location: Corridor A, B, C: Ground Floor

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
Clinical PET Oncology			
104	J. Cerci C.C. Pereira Neto J.J. Vitola	Brazil	Feasibility of Biopsy Guided by FDG-PET/CT in Oncological Patients
105	D. Sobic-Saranovic V. Artiko M. Todorovic- Tirnanic et al.	Serbia	Importance of 18F-FDG PET/CT Imaging in Patients with Lymphoma and Residual CT Mass after Treatment
106	V. Artiko D. Dobic-Saranovic N. Petrovic V. Obradovic	Serbia	PET/CT in Diagnosis of Metastases and Recurrences of Colorectal Carcinomas
107	V.E. Soroa M.M. Volpacchio J. Arashiro G. Rank et al.	Argentina	Pitfalls Encountered in 1500 Hybrid PET/CT Studies
113	S. Ozguven F. Dede T. Ones B. Gulluoglu	Turkey	Results of Initial FDG PET/CT Staging in Recently Diagnosed Breast Cancer Patients
114	S. Ozguven F. Dede T. Ones B. Gulluoglu	Turkey	Morpho-Metabolical Changes at the Operation Site in Recently Mastectomized Patients: Impact of Staging FDG PET/CT
115	S. Ozguven F. Dede T. Ones B. Gulluoglu	Turkey	Synchronous Metastases in Recently Diagnosed Breast Cancer: Role of Staging FDG PET/CT
117	M. Aras T. Ones F. Dede F. Novruzov	Turkey	The Value of FDG-PET/CT Imaging in Dermatomyositis as a Paraneoplastic Syndrome in Malignancy Suspicion

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
121	A. Koski K. Kairemo M. Oksanen A. Koskela et al.	Finland	Radiological Response Evaluation of Oncolytic Virus Treatment in Patients with Advanced Cancer
123	M.J. Jofré Manieu T. Massardo M.P. Sierralta J. Canessa et al.	Chile	FDG PET in Nephrouinary Cancer. Our Experience in 60 Cases
125	P. Choudhury M. Gupta A.K. Chaturvedi A. Dogra	India	Significant Impact of Mid Treatment 18-F FDG PET-CT as a Prognostic Indicator in the Management and Follow-up of Metastatic Breast Cancer
126	J. Canessa T. Massardo G. Castro M.J. Jofré Manieu et al.	Chile	Usefulness of FDG-PET in the Evaluation of Sarcomas from Diverse Origin
143	O. Alonso J.P. Gambini G. Lago J. Gaudiano et al.	Uruguay	Evaluation of Somatostatin Receptors in Prostate Cancer Lesions with Ga-68-DOTATATE PET-CT
150	Y.P. Dang Q. Wang	China	Clinical Study of 18F-FDG PET/CT in Diagnosis and Management of Lung Cancer
154	S. Karunanithi C.S. Bal A. Malhotra G.P. Bandopadhyaya	India	Evaluation of 18F-FDOPA PET-CT and its Comparison with 99mTc- GHA SPECT/CT in Detection of Recurrence in Patients with High Grade Primary Glioma
156	S. Jeph R. Kumar C.S. Bal A. Malhotra	India	Role of 18F-FDG PET/CT in Response Evaluation of Metastatic Gastrointestinal Stromal Tumours to Imatinib Mesylate: Indian Experience
158	K. Mai H.K. Vu C.P. Pham V.T. Pham et al.	Vietnam	Application of PET/CT Simulation in Radiation Planning at the Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi-Vietnam
161	J. Mihailovic S. Goldsmith R. Killeen A. Abi Ghanem	Serbia	Clinical Utility of FDG PET/CT in Patients with Lymphoma

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
164	L. Henzlová M. Mysliveček P. Koranda T. Papajík et al.	Czech Republic	Reliability of 18F-FDG PET/CT after 2 Cycles of Chemotherapy for Prognosis Prediction in Patients with Non-Hodgkin Lymphoma
165	H. Crhakova P. Koranda L. Henzlova M. Dockal et al.	Czech Republic	18F-FDG PET/CT under TSH Stimulation in Patients with Differentiated Thyroid Carcinoma
166	P. Brader Z. Gil Y. Fong T. Helbich et al.	ESR	Identification of Cancer Metastases Using the Combination of PET and Viral Vectors
168	J. Kunikowska L. Krolicki D. Pawlak I. Zerizer et al.	Poland	PET/CT Examinations with 68Ga-DOATATE in Neuroendocrine Tumors - Characterization of Physiological Uptake in Organs in Diagnosis of Primary Tumors
172	F. Martínez-Preciado M. Patiño-Zarco E. Estrada-Lobato F.O. García-Pérez et al.	Mexico	PET/CT with 11C-Acetate in Prostate Cancer: Appropriate Diagnostic Tool
180	M. Maltez Cruz	Mexico	Utility of 18 F-FDG PET-CT in Evaluation of Orbital Tumors
187	S.M. Carmona J. Santos L. Oliveira P. Colarinha et al.	Portugal	Diagnostic and Prognostic Value of 18F-FDG PET/CT on Cancer of Unknown Primary
188	J. Gerales Ferreira Azevedo dos Santos S. Carmona C. Bagulho L. Oliveira et al.	Portugal	Intra-Abdominal Neoplasms – MRI versus 18F-FDG-PET/CT
190	H. Le Ngoc H. Le Manh H. Le Duy T.H. Nguyen	Vietnam	Clinical Characteristics and 18F-FDG PET/CT Imaging in Differentiated Thyroid Carcinoma Patients with Negative 131I Whole-Body Scan and Elevated Serum Thyroglobulin

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
191	H. Amaral M. C. Gil H. Lavados F. Redondo et al.	Chile	PET/CT Imaging with 68Ga-DOTATATE in the Evaluation of Neuroendocrine Tumours (NET): Our Leading Experience in Chile
192	B. Khiewvan C. Nopmaneejumrusters P. Pusuwan P. Tujinda et al.	Thailand	Cost-Effectiveness Analysis of 18F-FDG PET/CT in Detecting Suspected Recurrence or Metastasis in Thyroid Carcinoma Patients with Negative Diagnostic Total Body Scan in Thailand: A Decision Analysis
195	P. Kundu Snehlata A. Malhotra C.S. Bal	India	18FDG PET-CT Role in Management of Dedifferentiated Thyroid Cancer
197	B. Khangembam C. Ball R. Kumar A. Malhotra	India	Role of 18F-FDG PET-CT in Medullary Thyroid Carcinoma and Correlation with Serum Calcitonin
199	K. Gourevich K.A. Busing A. Amit Z. Keidar	Israel	Early Assessment for Suspected Recurrent Ovarian Cancer - Optimizing PET/CT Performance Using a Tumor Marker Based Analysis
202	B. Rivera Bravo E. Estrada Lobato I.F. Vega González	Mexico	Impact of the 18F-FDG PET/CT on the Treatment and Management of Oncological Patients at the National Institute of Cancerology of Mexico
209	P. Bautista	Philippines	The Role of PET in the Evaluation of Treatment for Lymphoma: Philippine Setting
214	S. Gao L. Cai Y.S. Li	China	Clinical Study on Multiple Tracers PET/CT in Glioma
217	N.N. Mkhize M.D.T.H.W Vangu N.S. Perumal	South Africa	F-18 FDG PET-CT in Follow-up of Patients with Lymphoma
219	N. Malan N. N. Mkhize M.D.T.H.W Vangu	South Africa	68Ga-DOTATATE PET/CT Imaging: Preliminary Findings in Johannesburg, South Africa

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
220	J. Fruehwald- Pallamar C. Czerny B.S. Halpern M.E. Mayerhoefer	ESR	Relationship of Quantitative Measures Derived from (18)F-FDG PET/CT and Diffusion-Weighted MRI in Patients with Squamous Cell Carcinomas of the Head and Neck
225	J. Romanato R.O. Bezerra M.R. Menezes E.E. Camargo	Brazil	Role of Immediate [18F]FDG-PET/CT after Tumor Percutaneous Ablation as a Predictor of Local Recurrence-free Survival
230	M.A. Celis Lopez J.M. Lárraga- Gutiérrez	Mexico	18F-FLT for Stereotactic Radiotherapy Treatment Planning of Recurrent Brain Tumors: Experience of the National Institute of Neurology and Neurosurgery of Mexico
232	M. Patiño-Zarco I. Soldevilla-Gallardo O. García-Perez E. Estrada Lobato et al.	Mexico	Usefulness of 18F-FLT PET/CT in the Differential Diagnosis of Radiation Changes vs. Tumour Recurrence in the Follow-up of Patients with Primary Brain Tumours
233	R. De Juan P. Cotrina S. Ruiz A. Ruiz,	Spain	Additional Value of PET/CT-Based Radiotherapy Planning in Patients Diagnosed of Head and Neck Malignancy
234	J. Soares Junior R.M. Ferreira A.M.N. Coutinho E. Trindade et al.	Brazil	Clinical and Cost-Effectiveness of FDG-PET in Preoperative Staging of Non-Small Cell Lung Cancer (NSCLC) in Brazil: A Study in the Context of Brazilian Public Health System
236	F. Garcia-Perez E. Estrada Lobato M. Patiño-Zarco I. Soldevilla-Gallardo et al.	Mexico	Usefulness of 68Ga-DOTATOC PET/CT in the Evaluation of Patients with Medullary Thyroid Cancer and Suspected Recurrence
238	R. Chirico G. Bruno C. González E.P. Parma et al.	Argentina	Non-Invasive Characterization of Adrenals Masses Using 18FDG-PET/CT in Patient with Lung Cancer
239	C. Gonzalez G. Bruno R. Chirico Y. Blumenkrantz et al.	Argentina	Clinical Impact of PET/CT in Detecting Distant Malignant Compromise in Patients, Thought to Have Early and Locally Advanced Stages Breast Cancer

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
245	V. Rangarajan N.C. Purandare S. Shah A. Agrawal et al.	India	Impact of FDG PET/CT in the Initial Staging of Patients of Non-small Cell Lung Cancer: 4 Year Experience from a Tertiary Care Referral Cancer Centre in India
246	N. Purandare V. Rangarajan S. Shah A. Agrawal et al.	India	FDG PET/CT in Small Cell Lung Cancer: Initial Experience from a Tertiary Cancer Referral Centre in India
248	X.C. Nguyen W.W. Lee J.H. Chung S.Y. Park et al.	Vietnam	FDG Uptake, Glucose Transporter Type 1, and KI-67 Expressions in Non-Small-Cell Lung Cancer: Correlations and Prognostic Values
249	A. Kumar C.S. Bal A. Malhotra G.P. Bandopadhyaya	India	Role of 18F-DOPA PET/CT in the Evaluation of Neuroendocrine Tumors
250	P. Gupta A. Singh J. Shukla R. Kumar et al.	India	Role of [18F]FDG PET-CT and 99mTc(V)DMSA in the Management of Patients with Osteosarcoma
251	A. Nazar K. Rakesh C.S. Bal A. Malhotra	India	Role of Serial 18F-FDG PET/CT in Surveillance of Patients Treated for Colorectal Cancer
252	K. Agrawal B.R. Mittal R. Kashyap A. Bhattacharya et al.	India	Efficacy of F-18 FDG PET/CT in Detecting Recurrence in Patients with Epithelial Ovarian Carcinoma
254	M. Abrar B.R. Mittal K.K. Kamaleshwaran A. Bhattacharya et al.	India	Role of Whole Body PET/CT in Detecting Distant Metastasis in Head and Neck Cancer
258	P. Sharma R. Kumar C. Bal A. Malhotra	India	Comparison of 18-FDG PET-CT with Conventional Imaging for Detection of Suspected Recurrence in Patients with Endometrial Carcinoma

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
259	M. Haidar M. Haddad	Lebanon	3_-Deoxy-3_-18F-Fluorothymidine (18F-FLT) PET/CT in Patients with Primary Brain Tumors: Mount Lebanon Hospital Initial Experience
260	M. Haidar M. Haddad	Lebanon	18F-FDG PET-CT in the Management of Differentiated Thyroid Cancer
261	M. Haidar M. Haddad	Lebanon	Role of FDG-PET in the Restaging and Recurrent Breast Cancer
267	H. Kulkarni V. Prasad C. Schuchardt R.P. Baum	Germany	Correlation between Estimated Tumour Dose and Response to PRRNT as Determined by SMSreceptor PET/CT Using Ga-68 DOTATOC
268	M.P. Sierralta Carvajal I. Berrocal T. Massardo M.J. Jofre et al.	Chile	Testicular Cancer Assessment with PET-FDG
279	S.R. Paredes Fernandez J.A. Serna Macias L. Quiroz Castro N. Sánchez Casas et al.	Mexico	Usefulness of 18F-FDG PET/CT in the Assessment of the Response to Treatment of Patients with Lymphoma
280	F. Garcia-Perez E. Estrada-Lobato M. Patiño-Zarco I. Soldevilla-Gallardo et al.	Mexico	Usefulness of 68Ga-DOTA-d-Phe (1)-Tyr (3)-Octreotide (DOTATOC) PET/CT in Neuroendocrine Tumors
281	F. Garcia-Perez E. Estrada-Lobato M. Patiño-Zarco F. Martínez-Preciado et al.	Mexico	Prognostic Value of Metabolic Tumor Burden with 18FDG PET/CT in Diffuse Large B Cell Lymphoma
286	A.N.K. Al-Ibraheem K. Hermann A.J. Beer M. Schwaiger et al.	Jordan	Diagnostic Accuracy of FDG PET/CT in Recurrent Osseous and Soft Tissue Sarcoma: Comparison with Full-Dose Diagnostic CT
290	Z. Zhu C. Wu X. Li W. Cheng et al.	China	Improving Detection and Evaluation of Gastric Malignancies on PET/CT by Gastric Distension with Both Milk and Diatrizoate

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
294	L. Pushpalatha Sudhakar P. Singa J. Srikala P. Amber et al.	India	FDG PET-CT in Pre op Staging of Breast Cancer: Initial Experience from a Comprehensive Care Centre for Breast Diseases
299	B. Das J. Mantil	India	Histopathologic Correlation of 18F- FDG Uptake in Thyroid Malignancy
314	E. Özkan M. Araz Ç. Soydal N.Ö. Küçük	Turkey	The Role of 18F-FDG-PET/CT in the Preoperative Staging and Posttherapy Follow Up: Comparison with Spiral CT
315	E. Özkan Ç. Soydal M. Araz N.Ö. Küçük	Turkey	The Role of PET/CT in the Evaluation of Pancreatic Cancer and Suspected Pancreas Masses
317	V.H. Somasundaram P.S. Sundaram S. Goyal S.S. Palaniswamy et al.	India	18FDG PET-CT in Radiotherapy Planning – Comparison of Gross Tumor Volumes Obtained Using Automated Versus Manual Methods
318	B.R. Mittal K. Agrawal R. Kashyap A. Bhattacharya et al.	India	Usefulness of F-18 FDG PET in Evaluation of Adrenal Lesions in Patients with Lung Cancer
Clinical PET Cardiology			
291	N. Seshadri A. Sreedasyam I. Hufton S. Vinjamuri	United Kingdom	Feasibility and Utility of Assessment of Myocardial Viability Using 'Hybrid' 99mTc-MIBI SPECT and 18F-FDG PET Studies in a Remote PET Centre without Access to Cyclotron
327	A. Meave M.A. Peña M. Jiménez E. Aleksanderson	Mexico	Impact of Coronary Artery Disease (CAD) over Myocardial Blood Flow (MBF), Total Perfusion Defect (TPD) and Summed Differential Score (SDS) Evaluated with 13N-ammonia PET/CT
Clinical PET Neurology			
283	B. Chaushev A. Klisarova M. Arnaudova P. Bochev	Bulgaria	PET/CT in Early Diagnosis of Alzheimer's Disease and Alcohol Dementia: Case Report

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
296	K. Lakshmi K. Alfred Deepak A.C. Suresh Kumar V. Ramya et al.	India	Evaluation of Metastatic Brain Lesions in Whole Body F18FDG PET-CT of Oncological Cases in Correlation with Their Fasting Blood Sugar
Clinical PET Paediatrics			
198	P. Orellana N. Rojas M.A. Wiestruck C. Garcia et al.	Chile	PET-CT in Paediatric Oncologic Patients. Initial Experience in an University Hospital
320	J.P. Oliva González R.P. Baum	Cuba	One Day Protocol: Dual Tracer/Dual Isotope FDG-18 and Ga-68 DOTA-NOC PET/CT. Study of a Child with Neuroblastom to Determining the Metabolic Tumor Status

POSTERS

WEDNESDAY, 9 NOVEMBER 2011

Clinical PET II (Other applications) & Clinical non-PET

Location: Corridor A, B, C: Ground Floor

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
Clinical PET Others			
111	S.V. Solav R. Bhandari	India	Value of FDG PET Scan in Evaluation of Skeletal Infections
116	M. Aras F. Dede T. Ones F. Novruzov et al.	Turkey	Is FDG Uniformly Distributed Throughout the Skeleton in Females?
118	M. Aras T. Ones F. Dede S.S. Candemir et al.	Turkey	FDG PET/CT in Cancer Patients with Fibrous Dysplasia
119	S. Gungor T. Ones M. Aras F. Dede et al.	Turkey	FDG PET/CT Appearance of Multi-regional Elastofibroma
120	S. Gungor T. Ones F. Dede F. Novruzov et al.	Turkey	Diaphragmatic Schwannoma Mimicking Hydatid Cyst Depicted by PET/CT
170	A. Samarin L. Karusoo R. Brand I. Muoni et al.	Estonia	Atypical Presentation of Bronchiolitis Obliterans Organizing Pneumonia on 18FDG-PET/CT
207	I. Soldevilla Gallardo L.A. Medina Velázquez E. Estrada-Lobato M. Patiño Zarco et al.	Mexico	Utility of PET/CT with 18F-FDG (Fluorodeoxyglucose)-Labeled Leukocytes in the Diagnosis of Infectious Processes Associated with Oncological Pathologies: First Mexican Experience

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
216	N.N. Mkhize M.D.T.H. Vangu N.S. Perumal N. Malan	South Africa	Evaluation of Agreement between F-18 PET-CT and Tc-99m MDP Bone Scan Findings in Patients with Suspected Bone Metastases: Initial Johannesburg Experience
244	M. Mohiuddin N. Kavitha J.E. Rao D. Gauri et al.	India	Role of Whole Body 18F-FDG PET/CT in the Evaluation of Fever of Unknown Etiology
253	M. Abrar K. Manohar A. Bhattacharya B. Singh et al.	India	Methods of Normalization and Factors Affecting Liver and Mediastinal Blood Pool Standardized Uptake Values – A Multivariate Analysis
263	G. Estrada Sanchez L. Gonzalez-Maya J. Altamirano	Mexico	Comparison of Micro PET/CT Using 18FDG and Micro SPECT/CT Imaging of Glioblastoma α V β 3 Integrin Expression Using 99mTc Labeled RGD Peptide
271	J. Gambini Gonzalez A. Quagliata G. Lago J. Gaudiano et al.	Uruguay	Comparison of Ga-68 DOTATATE vs. Tc-99m HYNIC OCTREOTIDE Scan in Follow-up of Cancer Thyroid Patients with Raised Thyroglobulin and Negative I-131 WBS
273	H.M. Simonds J. Warwick A. Ellmann	South Africa	Introduction of PET-CT Scanning Impacts Treatment Decisions in the Management of Cervix Carcinoma Patients in a Public Hospital
276	Y.A. Onimode M.D.T.W.H. Vangu B.O.A. Osifo	Nigeria	Efficacy of PET/CT in the Management of the Tennis Syndrome: A Case Report
285	V. Ptacnik S. Bakalarova J. Kubinyi	Czech Republic	Focal Accumulation of FDG in Lung Parenchyma without Morphological Correlate on CT
287	V. Prasad M. Secknus D. Hoersch T. Kuntze et al.	Germany	Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Carcinoid Heart Disease (Hedinger's Syndrome): Prognostication of Efficacy by Ga-68 SMS Receptor PET/CT
288	V. Prasad D. Kaemmerer M. Hommann D. Hoersch et al.	Germany	Efficacy of Ga-68 Somatostatin Receptor PET/CT and Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumours of the Rectum

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
289	Z. Zhu C. Wu W. Cheng et al.	China	Brown Adipose Tissue Metabolism in Diabetic Mice and Weight-Loss Mice: A Preliminary Study with 18F-FDG MicroPET
306	M.C. Trinh Thi N.V. Tan V.K. Nam	Vietnam	Normal Uptake Value of 11Acetate in Some Organs
307	P. Unak S. Timur B.F. Ozkaya E. Ilker Medine et al.	Turkey	18FDG Conjugated Magnetic Nanoparticle Probes: Synthesis and In Vitro Investigation on MCF7 Breast Cancer Cells
311	V. Agarwal S. Pande S.K. Garg D.R. Jangid	India	FDG Embolus: Focal Lung Uptake without CT Abnormality- Potential Pitfall in PET-CT Fusion Imaging
Clinical non-PET Oncology			
102	S. Sergieva E. Alexandrova G. Baichev N. Nikolova et al.	Bulgaria	Role of SPECT-CT in Cancer Patients for Diagnosis of Bone Metastases
131	N.Y. Voit O.I. Solodyannikova	Ukraine	SPECT with 99mTc-MIBI and 99mTc-(V)DMSA in the Assessment of Breast Lesions: Comparative Study with Planar Scintimammography
132	O.I. Solodyannikova G.G. Sukach	Ukraine	SPECT in Diagnostic of Metastatic Medullary Thyroid Cancer
141	S.S. Palaniswamy P. Subramanyam D.K. Vijaya Kumar P. Kumar	India	Sentinel Lymph Node Scintigraphy & Gamma Probing in Patients with Early Stage Ca Cervix
159	M. Havel O. Kraft	Czech Republic	Our First Experience with SPECT/CT in Oncology
173	M.C. Martínez A. Martí A. De los Reyes A. Llamas et al.	Colombia	177Lu-DOTATATE: Management of Metastatic Well Differentiated Neuroendocrine Carcinomas in the National Cancer Institute of Bogota Colombia

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
194	G.G. Khachatryan K.V. Khondkaryan R.G. Khachatryan A.G. Karapetyan	Armenia	Early Differential Diagnostics of Oncopathology of Neck Area and Mediastinum, with Radiological Methods of Diagnostics
210	P.A. Bautista E.B. Cruz	Philippines	The Use of SPECT-CT in Determining Y-90 Microspheres Distribution Post Selective Internal Radiation Therapy: Preliminary Experience in the Philippines
218	M.D.T.H.W. Vangu N. Malan N.N. Mkhize	South Africa	SPECT/CT: An Essential Adjunct in the Routine Management of Differentiated Thyroid Carcinoma
228	S. Ray S.K. Sharma	India	Incremental Value of SPECT-CT in Tumour Imaging
229	S. Sandoval Borrego B. Rivera Bravo R. Garibay Virues L. Villalvazo Gutierrez	Mexico	Usefulness of SPECT-CT 99mTc-Tetrofosmin Scintigraphy for the Diagnosis and Follow up of Patients with Lung Cancer
235	F.O. García-Pérez E. Estrada-Lobato M. Patiño-Zarco I. Soldevilla-Gallardo et al.	Mexico	Clinical Usefulness of SPECT/CT with 99mTc-29-41 Ubiqicidin in Cancer Patients with Suspected Infectious Process
243	A. Mhiri I. Slim I. Meddeb M.F. Ben Slimane	Tunisia	Incremental Value of Diagnostic 131I SPECT/CT Fusion Imaging in Assessment of Patients with Differentiated Thyroid Carcinoma
293	D. Prawiro E. Purnomo	Indonesia	High Dose 50 mCi or 100 mCi NaI-131 in Preventive Thyroablation of Thyroid Remnant in Patients with Differentiated Thyroid Cancer
297	H. Singh R. Kumar C.S. Bal A. Malhotra	India	Incremental Value of SPECT-CT over Planar Scintigraphy and SPECT for the Evaluation of Suspected Bone Metastasis in Patients with Breast Cancer
312	A. Llamas-Olier M.C. Martínez L. Rojas E. Angarita et al.	Colombia	Empirical High-Dose I-131 Therapy in Patients with Increased Thyroglobulin and no Detectable Anatomical Lesions

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
321	C.F. Calderón Marín J.J. González González J.P. Oliva González	Cuba	Using the Hypoxia Volume Distribution for Calculation of Tumor Control Probability (TCP)
Clinical non-PET Cardiology			
112	I. Berrocal G. Castro Mora M. Paz Muñoz N. Santis	Costa Rica	Functional and Morphological Parameters of the Left Ventricle in Patients with and without Coronary Artery Disease with Gated Myocardial Perfusion SPECT
142	P. Subramanyam P. Shanmuga Sundaram S. George V. Harish et al.	India	Tc 99m Mibi Infusion & Low Dose Dobutamine Gated SPECT - A Novel Myocardial Viability Detection Protocol in Ischaemic Cardiomyopathy
153	A. Verma A. Kumar R. Jeyachandran S. Balani	India	A Dual Isotope Rest SPECT Myocardial Perfusion Scintigraphy (DI-R-MPI): Improved Efficacy in the Detection of Myocardial Viability
162	A. Puente C. Martínez F. García J.L. Aceves	Mexico	Coronary Artery Disease Functional Assessment with Gated Myocardial Perfusion SPECT
204	S. Merlano Gaitán R. Murgueitio Cabrera E. Rodríguez Ferro	Colombia	Myocardial Perfusion Imaging in Patients with Chagas Disease; Utility
205	R. Murgueitio Cabrera G.S. Merlano Gaitán E. Rodríguez Ferro	Colombia	Prognostic Value of Myocardial Perfusion Study on Population over 75 Years
211	A.P. Quinon J.M. Obaldo	Philippines	Incremental Prognostic Value of Perfusion Defects in Patients with Scintigraphic Evidence of Left Ventricular Dysfunction
212	A.P. Quinon A.G. Serna R. Tenorio F. Dianco et al.	Philippines	Quantification of Left Ventricular Parameters in Normal Adult Filipinos using Cardiac MRI, Gated SPECT Thallium-201 and 2D Echocardiogram
221	E. Garcia Nicacio A.R. Rodríguez	Mexico	Scintigraphic Evaluation of Cardiac Disorders in Antiphospholipids Antibodies Syndrome

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
282	M.C. Martinez A. Puente C. Trejo	Mexico	Utility of the Complete Left Bundle Branch Block (LBBB) as Prognostic Factor of Cardiac Failure in Patients with Defects of Myocardial Perfusion Evaluated with Gated-SPECT
322	L.O. Cabrera Rodriguez K. Padrón R. Carrillo Y. Fernández et al.	Cuba	Value of Post-NTG Left Ventricular Volume and Ejection Fraction by Gated Myocardial Perfusion SPECT in Assessment of Viability in Patients with Myocardial Infarction
Clinical non-PET Neurology			
144	L.B. Kuanova G.O. Ryskulova A.S. Kassenova	Kazakhstan	Clinical Value of SPECT with Poststroke Dementia
185	L.M. Pabón Castilla E. Manzi	Colombia	99mTc-TRODAT-1 SPECT Imaging of Dopamine Transporter in Early Diagnosis of Parkinson's Disease
270	Z.M. Jawa A. Ellmann	Nigeria	Radionuclide Cisternography in the Era of PET
292	A. Sreedasyam N. Seshadri M. Carroll S. Vinjamuri	United Kingdom	Value of Combined Brain Blood Flow and Dopamine Transporter Imaging in Patients with Dementia
298	L. Pushpalatha Sudhakar S. Jayalakshmi Sita P. Manas D. Ravivarma	India	Ictal SPECT in Paediatric Epilepsy of Temporal Lobe Origin – Correlation with Surgical Outcome
Clinical non-PET Paediatrics			
103	K.M.C. Dela Cruz T.N.B. Pascual R.A.O. Conlu V.P.O. Magboo	Philippines	Atypical Bone Scintigraphy Patterns in a Child with Acute Lymphoblastic Leukaemia: A Case Report
Clinical non-PET Others			
124	M. Garcheva- Tsacheva I. Kostadinova N. Temelkova G. Ganchev	Bulgaria	Additional Value of SPECT-CT in the Diagnosis of Primary Hyperparathyroidism
152	I. Kostadinova	Bulgaria	Our Impressions from Application of SPECT-CT in Patients with a Suspicion of Infection of Joint Prosthesis in Comparison with those with Combined Method for Leukocyte's and Bone Marrow Scintigraphy

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
176	O. Lang I. Kuničová	Czech Republic	Leukocyte SPECT/CT for Diagnosis of Osteomyelitis in Patients with Diabetic Foot
178	N. Rasulova V. Lyubshin K. Hwan Kim F. Djalalov	Uzbekistan	Strategy of Bone Metastases Treatment in Patients with Impending Cord Compression or Vertebral Fractures: A Pilot Study
184	V.P. Marino C.J. Simal S.M. Dumont M.C. Nunes et al.	Brazil	123I-MIBG Imaging Cardiac Autonomic Neuropathy in the Chronic Chagas Cardiopathy
240	C. Liu X. Liu Z. Luo J.J. Zaknun	China	Whole Body Imaging with Lu[177]-EDTMP: Extended Phase II Clinical Trial Investigation of Lu[177]- EDTMP for the Palliation of Metastatic Bone Pain
241	M.F. Ben Slimane I. Slim I. El Bez M. Ghzaïel	Tunisia	Adjuvant Treatment with Radioactive I-131 in Malignant Struma Ovarii
242	I. Slim A. Mhiri L. Zaabar M.F. Ben Slimane	Tunisia	Value of SPECT/CT Scintigraphy in the Assessment of Patients with Hyperparathyroidism
264	X. Liu C. Liu H. Li Z. Luoc et al.	China	177 Lu-EDTMP for Bone Pain Palliation in Metastatic Prostate and Breast Cancer: A Phase II Trial
266	H. Kulkarni V. Prasad C. Schuchardt R.P. Baum	Germany	Is There a Correlation between Peptide Receptor Radionuclide Therapy Associated Hematological Toxicity and Spleen Dose?
316	N. Ozlem Kucuk C. Soydal S. Lacin E. Ozkan et al.	Turkey	Intra-Arterial Radioembolization with Y-90 for Unresectable Primary and Metastatic Liver Tumors

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
319	F.M. Quintero Alvarez J.C. Ramirez Fontalvo I.F. Vega Gonzalez G.M. Camacho Garcia	Colombia	The Prevention of Sialadenitis Post-Therapy with I-131 in Patients with Thyroid Cancer Reduces the Dose of Radiation in the Salivary Glands
328	A. Shimoni I. Avivi J. Rowe S.T. Zwas et al.	Israel	A Multi-center Prospective Randomized Study Comparing Yttrium-90 Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) versus BEAM Alone Prior to Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphoma
329	A. Guensi M. Aitidir H. Belfaik M. Kebbou	Morocco	SPECT Bone Scan Limits
330	N. Watanabe M. Yoshizumi S. Tanada Y. Sasaki	Japan	Imaging Cancer Therapeutic Trastuzumab Bound on Breast Cancer Cells with ¹¹¹ In-Biotin-Bn-EDTA-Anti-Human IgG1 Monoclonal Antibodies Followed by the Injection of Macroaggregated Albumin-Avidin Conjugate Chase
333	A. Malhotra P. Gupta U. Pandey S. Saxena et al.	India	Phosphorus 32 (³² P) Skin pTch for the Treatment of Basal Cell Carcinoma
336	Z.M. Jawa	Nigeria	Outcome of Radioactive Iodine Therapy in Hyperthyroid HIV Positive Patients

POSTERS

THURSDAY, 10 NOVEMBER 2011

**Radiopharmacy PET, Radiopharmacy non-PET,
Instrumentation and Quality Control, Dosimetry and
Radiation Safety, Education and Training,
Planning/Establishing/Experiences PET Centres**

Location: Corridor A, B, C: Ground Floor

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
Radiopharmacy PET			
100	C. Gameiro-Paris B. Lambert C. Sauvage D. Caron	Belgium	Automated Synthesis and Quality Control of Apoptosis PET Probe -18F-ML-10 with Multipurpose Platform
101	C. Gameiro-Paris B. Lambert J.J. Cavalier C. Sauvage	Belgium	Optimized Production of 18F-Labeled Beyond FDG Radiopharmaceuticals with Automated Platform
128	J.M. Geets D. Blampain C. Gameiro-Paris	Belgium	Building a Radiopharmaceutical Cyclotron Production Centre from Greenfield
129	J.M. Geets E. Kral M. Ghyoot	Belgium	Doubling the Current on IBA PET Cyclotrons and Other Enhancements
138	A.R. Jalilian M. Ghannadi-Maragheh	Iran, Islamic Republic of	Current Status of PET Radionuclides and Radiopharmaceuticals Production in Iran
146	S.K. Nandy M.G.R. Rajan	India	A Fully Automated Radiosynthesis of 4-[F-18]Fluorobenzaldehyde: A Synthone for Amine-Oxy Peptide Labelling
147	S.K. Nandy M.G.R. Rajan	India	A Simple Fully Automated One-pot Synthesis of 3'-Deoxy-3'-[F-18]Fluorothymidine
148	S.K. Nandy M.G.R. Rajan	India	A Single Column Purification Technique for the Fully Automated Radiosynthesis of [F-18]Fluoroacetate: A Potential Acetate Analog for Prostate Tumor Imaging
149	S.K. Nandy M.G.R. Rajan	India	A Single Column Purification Technique for the Fully Automated Radiosynthesis of [F-18]Ethyl Fluoroacetate([F-18]EFA) as a Proradiotracer of [F-18]Fluoroacetate([F-18]FA) for the Measurement of Glial Metabolism by PET

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
163	A. Speranza S. Del Vecchio B. Alfano L. Pace et al.	Italy	[18F]-FLT Purification by SPE Method in a Fully Automated Synthesis Procedure Using a Commercial Synthesizer
186	V. Sciani M. Figols de Barboza R. Herrerias L.C. Sumiya et al.	Brazil	18F-FDG Production Experience at IPEN-CNEN-SP
196	G.V. Tostes C.A. Buchpiegel M.R. Okamoto A.T. Garcez	Brazil	Critical Factors for a Successful Installation of a Cyclotron Site
200	S. Fatima M.A. Khan J. Irfan	Pakistan	Judicious Use of PET-Cyclotron Facility in Developing Countries
201	S. Fernández J. Giglio H. Cerecetto A. Rey	Uruguay	Synthesis and Preliminary Evaluation of a 68Ga-DOTA Complex with a Nitroimidazol Moiety as Potential Radiopharmaceutical with Selectivity towards Hypoxic Tissue
203	V. Trindade Ferré J. Giglio E. Vasilskis P. Oliver et al.	Uruguay	Optimization of 68Ga-DOTA-TATE Labelling for the First PET Clinical Applications in Uruguay
213	D. Pawlak W. Wojdowska J. Kunikowska L. Krolicki et al.	Poland	68Ga Labeling of DOTATATE for Clinical Application, Polish Experience
215	L.G. Carvalho J.A. Osso Junior M. Figols de Barbosa V. Sciani et al.	Brazil	Development of the Radiopharmaceutical 18F-Acetate for Detection of Primary Tumor of Breast and Prostate
227	S. Chakraborty R. Chakravarty H.D. Sarma T. Das et al.	India	Preparation and Preliminary Studies on 68Ga-labeled cyclic RGD Peptide Dimer as a Potential PET Radiotracer for Tumor Imaging

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
272	R.F. Costa J.A. Pires R. Herrerias J.A. Osso Junior et al.	Brazil	Methods of Purification of ⁶⁸ Ga for Biomolecules Labelling
275	M. Jiang M. Shokeen R. Ferdani C.J. Anderson	United States of America	Preparation and Biological Evaluation of ⁶⁴ Cu-CB-TE1A1P-LLP2A, a Peptidomimetic Ligand Targeting $\alpha 4\beta 1$ -Positive Tumors with High Affinity and Stability
303	A. Coronel A. Durán V. Copa	Argentina	PET Radiopharmaceutical Regulations: A Tricky Situation
304	A. Durán S. Martinez Visiedo F. Müller M. Diaz et al.	Argentina	FDG Production Experience at FCDN. The First Four Years
305	I. Aljammaz B. Al-Otaibi S. Amer J. Amartey et al.	Saudi Arabia	Preclinical evaluation of Fluorine-18 Labeled Bombesin Peptide Analogs as Potential PET Radiopharmaceuticals for Breast Cancer Imaging
309	A. Dash R. Chakravarty M. Venkatesh	India	Development of a Novel Ge-68/Ga-68 Generator for Biomedical Applications
310	R. Chakravarty T. Das A. Dash M. Venkatesh	India	Validation of the Nano-Ceria-Polyacrylonitrile Composite Based Ge-68/Ga-68 Generator for the Routine Clinical Preparation of Ga-68-DOTATATE
326	A.H. Al Rayyes S. Kelani M. Al Jamal E.T. Gazoul et al.	Syrian Arab Republic	High Yield Reliable Automated System for the Production of ¹⁸ F-Choline
Radiopharmacy non-PET			
108	T. Teixeira Guimarães A. Bordim M. de Souza Albernaz R. Santos-Oliveira	Brazil	The Quality Control of ⁹⁹ Tcm-MAG3 Radiopharmaceutical

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
109	A. Bordim B.F. de Carvalho Patricio A. Silva Fusco R. Santos-Oliveira et al.	Brazil	Nanoradiopharmaceuticals for Nuclear Medicine
110	R. Santos-Oliveira L. Jorge Antunes M. de Souza Albernaz A. Bordim	Brazil	Radiopharmaceuticals in Numbers: Brazil
130	S. Malja B. Daci K. Schomaecker M. Alikaj	Albania	Quality Control of Labeled MDP - 99mTc with Different Chromatographic Systems
133	B. Daci S. Malja K. Schomaecker M. Alikaj	Albania	Comparative Evaluation of Chromatographic Methods for Radiochemical Purity Control of 99-Mo Generator Eluate
135	M. De Marco S. Maggi	Italy	Good Radiopharmacy Practice in the Preparation of Radiopharmaceuticals – A Practical Implementation
157	S. Ozvatan A. Tanrikut S. Unal A.N. Yuksel	Turkey	TAEK Proton Accelerator Facility and Radiopharmaceuticals Production
265	N. Delgado Lopez A. De los Reyes F. Arguelles C. Villamil et al.	Colombia	Design and Build Up of the First Hospital Radiopharmacy with Standard USP and GRPhP in Colombia
Instrumentation and Quality Control			
151	M. Núñez Rodríguez F. Mut J. Cánepa K. Erlandsson et al.	Uruguay	Use of a Novel Acquisition Strategy to Facilitate Respiratory Motion Correction and Evaluation of Potential Impact in Lung SPECT
189	A.T. Garcez D. Yanikian Nersissian C. Chow Robilotta	Brazil	GE Discovery 690 Performance Reference Tests

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
222	A.H. Ng Z. Kayun Farni B. Sapiin H.S. Soh	Malaysia	Implementation of Quality Assurance Programme (QAP) in PET Centre in Malaysia
223	M.R. Herrera Rodríguez X. López Rendón H. Vera Hermosillo S.L. Soto Gutiérrez	Mexico	The Importance of Having a Quality Control Program for a Hybrid Equipment SPECT-CT, Considering the Financial Cost and the Equipment Downtime
224	H.S. Soh A.H. Ng	Malaysia	Development of Low-Cost Phantom for Positron Emission Tomography-Computed Tomography (PET-CT) Performance Tests
237	A. Mohd Zain S.A. Sarji A. Mohamed K.H. Ng et al.	Malaysia	An Overview of the Installation Project of a SPECT/CT (BrightView XCT) in Malaysia
323	J. An B. Yue	China	Measurement Methods and Realization of PET/CT Image Fusion Accuracy
324	S. Chen	China	Quality Management and Artifact Recognition of PET/CT in Oncology
Education and Training			
136	R. Morales R. Cano Pérez	Peru	Planning and Education of a Multidisciplinary Team to Implement PET/CT in Peru
167	F. Berger M.F. Reiser	ESR	Biomedical Imaging in the Era of Molecular Medicine: PET-CT Versus Alternate Clinical Modalities
182	C.L. Vetere P.R. Gomiz J.C. Furnari	Argentina	A Tool to Facilitate Collaboration and Training in Nuclear Medicine for Latin America
257	M.A. Abdul Khader F. Hamzah S. Ibrahim Ludfi W.A. Wan Kamil	Malaysia	Setting up and Implementing a Nuclear Medicine Specialty Training Programme in a Service Hospital and University Set up: Experience from Malaysia
Planning/Establishing/Experiences PET Centres			
140	N. Rauhala J. Niemelä H. Korpela R. Bly	Finland	Survey on the Use of SPECT-CT and PET-CT Devices in Finland in 2011

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
145	F. Hasford E.K. Nani J.H. Amausi	Ghana	Improving Diagnostic Accuracy in Molecular Nuclear Medicine in Ghana
169	S. Nazarenko A. Samarin L. Karusoo R. Brand et al.	Estonia	How to Make PET-CT Feasible in Countries with Limited Economic Resources: Estonian Experience
171	L. Karusoo A. Samarin R. Brand I. Muoni et al.	Estonia	FDG-PET/CT and Mediastinoscopy in Mediastinal Staging of Lung Cancer: Case Report
174	J. Giglio Barossi V. Trindade L. Reyes E. Valsiskis et al.	Uruguay	Implementing a Hospital Radiopharmacy in the Uruguayan Center of Molecular Imaging
179	M.F. Kabir K. Afroj N. Islam M.N. Hossain	Bangladesh	Challenges in Establishing PET/CT-Cyclotron Facility in a Developing Country – Bangladesh Experience
183	E. Slobina N.N. Alexandrov	Belarus	The National Cancer Program of Belarus to Increase Capacity for Oncology: Barriers to Implementation of New Technologies in Radiation Oncology
206	H.S. Bom	ARCCNM	Current Status and Perspective of Clinical PET in Korea
226	A.A. Al-Sugair	Saudi Arabia	Over One Decade of Experience in PET Imaging at KFSH&RC-Riyadh, Saudi Arabia
269	A. Dustov	Tajikistan	Nuclear Cardiology in Tajikistan
274	G. Kanafin Y.A. Akhmetov T.R. Konurbayev Y.N. Ilin	Kazakhstan	The Experience of Establishment of First PET/CT Centre in Kazakhstan
277	N.V. Kravtsova J.A. Utesheva	Kazakhstan	Tumor Markers Investigation in Everyday Practice of Reproductive Health Clinic in Kazakhstan
284	F.I. Peer	South Africa	Reflection on the Challenges of Establishing PET in Emerging Countries
300	Z. Arifin	Indonesia	Challenges of Licensing on Clinical PET and Molecular Nuclear Medicine in Indonesia

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
301	F. Mohammed S. Asa'ad	Yemen	The Impact of Establishment of the First Nuclear Medicine Centre in Yemen in 2008, the Challenges and its Effect on Medical Management, Treatment and Outcomes
313	A. De los Reyes A. Llamas-Olier	Colombia	Medical Cyclotron Project at the National Cancer Institute in Bogota Colombia: A Successful Partnership with IAEA
334	N. Ben Raïs H. Guerrouj R. Ouboukdir I. Ghfir	Morocco	Implementation of Hybrid Imaging in Morocco
337	C. Artner A. Zipper M. Nader	Austria	Modern Technologies of Logistics Network Creation for Short-Lived Isotopes
Dosimetry and Radiation Safety			
122	A.J. Cárdenas Solano	Peru	Internal Dosimetry Hyperthyroid Patients by Quantification in Live: Method of Images Conjugate
127	P. Tandon M. Venkatesh S.A. Hussain	India	Radiation Dose to the Personnel Handling 18F-FDG and Dose Reduction Methods
139	A. Gupta P. Sharma S. Tayal R. Sengupta et al.	India	Practical Radiation Safety Issues for Ensuring Safe Working Environment in a High Volume PET Centre in India
155	F.E. Trujillo Zamudio	Mexico	Medical Physicist Role for a Nuclear Medicine Building Project at "Hospital Regional de Alta Especialidad de Oaxaca" According to Mexican Regulatory Agency and IAEA Human Health Reports No. 1, (2010)
175	L. Donadille M. Sans Merce S. Baechler I. Barth et al.	France	Extremity Dosimetry in Nuclear Medicine: Results of the ORAMED Collaboration
177	A.L. Kesner N.C. Freedman	Israel	Measuring through the Noise - Using Mean Raw Pixel Counts to Characterize the SUV's Bias on Differing Count Statistics Encountered in Gating Scenarios
262	A. Elliyanti Y. Fitri P.T. Wahyuni E.Y. Mailinatri	Indonesia	Evaluation of patient radiation dose during Nuclear Medicine Investigations at Dr.M.Djamil Hospital- Padang- Indonesia

<i>No of Poster IAEA-CN-185-</i>	<i>Name</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
278	M.A. Arciniegas Alvarez H. Alejo Martínez C.A. De los Reyes	Colombia	Presentation of a Practical Tool for Shielding Calculation in PET/CT Facilities
308	Y.T. Ramírez-Garzón O. Ávila L.A. Medina M. Patiño-Zarco et al.	Mexico	Measurement of Radiation Exposure in Relatives of Thyroid Cancer Patients in 131I Treatment

PARTICIPATION IN IAEA SCIENTIFIC MEETINGS

Governments of Member States and those organizations whose activities are relevant to the meeting subject matter are invited to designate participants in IAEA scientific conferences and symposia. In addition, the IAEA itself may invite a limited number of scientists as invited speakers. Only participants designated or invited in this way are entitled to present papers and take part in the discussions.

Representatives of the press, radio, television or other information media and members of the public, the latter as 'observers', may also be authorized to attend, but without the right to take part in the proceedings.

Scientists interested in participating in any of the IAEA meetings should request information from the Government authorities of their own countries, in most cases the Ministry of Foreign Affairs or national atomic energy authority.

PUBLICATIONS

Proceedings

The proceedings of the conference containing invited presentations and full papers of selected abstracts delivered as poster presentation at the meeting, as well as the findings and recommendations, will be published by the IAEA as soon as possible after the conference.

Orders

All IAEA publications may be ordered at the Information Desk or directly from:

Marketing and Sales Unit
Publishing Section
International Atomic Energy Agency
Vienna International Centre
PO Box 100
1400 Vienna, Austria
Fax: (+43 1) 2600-29302
Email: sales.publications@iaea.org
<http://www.iaea.org/books>

IAEA PUBLICATIONS RELATED TO THE SUBJECT OF THE CONFERENCE

STI/PUB/1393	IAEA Human Health Series No. 1: Quality Assurance for PET and PET/CT Systems	2009
STI/PUB/1381	IAEA Human Health Series No. 2: Quality Assurance Programme for Screen-film Mammography	2009
STI/PUB/1425	IAEA Human Health Series No. 4: Comprehensive Clinical Audits of Diagnostic Radiology Practices: A Tool for Quality Improvement. Quality Assurance Audit for Diagnostic Radiology Improvement and Learning (QUAADRIL)	2010
STI/PUB/1394	IAEA Human Health Series No. 6: Quality Assurance for SPECT Systems	2009
STI/PUB/1416	IAEA Human Health Series No. 8: Clinical Translation of Radiolabelled Monoclonal Antibodies and Peptides	2009
STI/PUB/1438	IAEA Human Health Series No. 9: Appropriate Use of FDG-PET for the Management of Cancer Patients	2010
STI/PUB/1457	IAEA Human Health Series No. 11: Planning a Clinical PET Centre	2010
STI/PUB/1491	IAEA Human Health Series No. 16: Atlas of Bone Scintigraphy in the Developing Paediatric Skeleton: The Normal Skeleton Variants and Pitfalls	2011
STI/PUB/1482	IAEA Human Health Series No. 17: Quality Assurance Programme for Digital Mammography	2011
STI/PUB/1498	IAEA Human Health Reports No. 4: Implementation of the International Code of Practice on Dosimetry in Diagnostic Radiology (TRS 457): Review of Test Results	2011
IAEA-TECDOC-1605	IAEA TECDOC No. 1605: A Guide to Clinical PET in Oncology: Improving Clinical Management of Cancer Patients	2008
IAEA-TECDOC-1597	IAEA TECDOC No. 1597: Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System	2008

IAEA-TECDOC-1549	IAEA TECDOC No. 1549: Criteria for Palliation of Bone Metastases — Clinical Applications	2007	IAEA-TCS-50	Training Course Series No. 50: Clinical Training of Medical Physicists specializing in Nuclear Medicine	2011
IAEA-TECDOC-1414	IAEA TECDOC No. 1414: Development of Kits for 99mTc Radiopharmaceuticals for Infection Imaging. Report of a co-ordinated research project 2000–2003	2004	IAEA-TCS-39	Training Course Series No. 39: Competency Based Hospital Radiopharmacy Training	2010
IAEA-TECDOC-1608	IAEA TECDOC No. 1608: Nuclear Medicine in Thyroid Cancer Management: A Practical Approach	2008	STI/PUB/1405	IAEA Radioisotopes and Radiopharmaceuticals Series No.1: Technetium-99m Radiopharmaceuticals: Status and Trends	2010
IAEA-TECDOC-1537	IAEA TECDOC No. 1537: Strategy and Methodology for Radioactive Waste Characterization	2007	STI/PUB/1348	IAEA Nuclear Security Series No. 9: Security in the Transport of Radioactive Material	2008
IAEA-TECDOC-1603	IAEA TECDOC No. 1603: The Role of PET/CT in Radiation Treatment Planning for Cancer Patient Treatment	2008	STI/PUB/1387	IAEA Nuclear Security Series No. 11: Security of Radioactive Sources	2009
IAEA-TECDOC-1430	IAEA TECDOC No. 1430: Radioisotope Handling Facilities and Automation of Radioisotope Production	2004	STI/PUB/996/CD	IAEA Safety Series No. 115/CD: International Basic Safety Standards for Protection against Ionizing Radiation and for the Safety of Radiation Sources (CD-ROM Edition, 2003)	2003
IAEA-TECDOC-1498	IAEA TECDOC No. 1498: Development of Radioimmunometric Assays and Kits for Non-clinical Applications – Proceedings of a final research coordination meeting held in Vienna, 6–10 December 2004	2006	STI/PUB/1117	IAEA Safety Standards Series No. RS-G-1.5: Radiological Protection for Medical Exposure to Ionizing Radiation. Safety Guide	2002
STI/PUB/1141	Non-serial Publications: IAEA Quality Control Atlas for Scintillation Camera Systems	2003	STI/PUB/1192	IAEA Safety Standards Series No. GS-G-1.5: Regulatory Control of Radiation Sources. Safety Guide	2004
STI/PUB/1198	Non-serial Publications: Nuclear Medicine Resources Manual	2006	STI/PUB/1465	IAEA Safety Standards Series No. GSR Part 1: Governmental, Legal and Regulatory Framework for Safety. General Safety Requirements Part 1	2010
STI/PUB/1342	Non-serial Publications: Operational Guidance on Hospital Radiopharmacy. A Safe and Effective Approach	2008	STI/PUB/1417	Safety Reports Series No. 63: Release of Patients After Radionuclide Therapy	2009
STI/PUB/1371	Non-serial Publications: Quality Management Audits in Nuclear Medicine Practices	2009	STI/PUB/1207	Safety Reports Series No. 40: Applying Radiation Safety Standards in Nuclear Medicine	2005
STI/PUB/1344	Non-serial Publications: Strategies for Clinical Implementation and Quality Management of PET Tracers	2009	STI/PUB/1118	Safety Reports Series No. 21: Optimization of Radiation Protection in the Control of Occupational Exposure	2002

STI/PUB/1366	Safety Reports Series No. 60: Radiation Protection in Newer Medical Imaging Techniques: Cardiac CT	2009
STI/PUB/1343	Safety Reports Series No. 58: Radiation Protection in Newer Medical Imaging Techniques: PET/CT	2008
STI/DOC/010/458	Technical Reports Series No. 458: Comparative Evaluation of Therapeutic Radiopharmaceuticals	2007
STI/DOC/010/470	Technical Reports Series No. 470: Therapeutic Radionuclide Generators: 90Sr/90Y and 188W/188Re Generators	2009
STI/DOC/010/471	Technical Reports Series No. 471: Cyclotron Produced Radionuclides: Guidelines for Setting Up a Facility	2009
STI/DOC/010/468	Technical Reports Series No. 468: Cyclotron Produced Radionuclides: Physical Characteristics and Production Methods	2009
STI/DOC/010/465	Technical Reports Series No. 465: Cyclotron Produced Radionuclides: Principles and Practice	2008
STI/DOC/010/459	Technical Reports Series No. 459: Labelling of Small Biomolecules Using Novel Technetium-99m Cores	2007
STI/DOC/010/466	Technical Reports Series No. 466: Technetium-99m Radiopharmaceuticals: Manufacture of Kits	2008

2011

International Conference on Research Reactors: Safe
Management and Effective Utilization
14–18 November, Rabat, Morocco

2012

3rd International Conference on NPP Life Management (PLIM) for
Long Term Operations (LTO)
14–18 May, Salt Lake City, UT, USA

13th International Symposium on Biological and Environmental
Reference Materials (BERM 13)
25–29 June, Vienna, Austria

International Symposium on Managing Soils for Food Security
and Climate Change Adaptation and Mitigation
23–26 July, Vienna, Austria

24th Fusion Energy Conference
8–13 October, San Diego, USA

International Conference on Radiation Protection in Medicine –
Setting the Scene for the Next Decade
3–7 December, Bonn, Germany

For information on forthcoming scientific meetings, please consult
the IAEA web site: <http://www.iaea.org/>

NOTES

NOTES

NOTES